Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC01LS Safety and PK in Healthy Adults
NCT02599896Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC01LS in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and tolerability of VRC01LS at 48 weeks. Started Nov 2015; status: completed.
02
Drugs
VRC01LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02599896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599896.